Drug Profile
Research programme: antimicrobial therapeutics - Vast Therapeutics/University of North Carolina
Alternative Names: BIOC 11; BIOC 51Latest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Novoclem Therapeutics; University of North Carolina at Chapel Hill
- Developer Vast Therapeutics
- Class Antibacterials
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Cystic fibrosis-associated respiratory tract infections
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Inhalation)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections in USA (Inhalation)
- 22 Oct 2019 Pharmacodynamics data from a preclinical study in Bacterial infections released by Vast Therapeutics